Stocks · News reference
TD Cowen Reiterates Buy on DexCom, Maintains $95 Price Target
TD Cowen analyst Joshua Jennings reiterates DexCom (NASDAQ:DXCM) with a Buy and maintains $95 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ViCentra Presents Large-Scale Real-World Evidence Demonstrating Kaleido Insulin Patch Pump System Delivers Stable Glucose Control with Very Low Hypoglycemia
ViCentra announced real-world data from 3,918 adults showing its Kaleido insulin patch pump system achieved 72.2% median time in range with minimal hypoglycemia (0.21% time below 54 mg/dL) and low glycemic variability (28.7% coefficient of variation) across Germany, the Netherlands, and France. The system, integrated with Diabeloop's DBLG1 algorithm and Dexcom G6, demonstrated strong clinical performance in routine use with high user engagement.
The Insider Report: The Leaders Have Taken Off
Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the
Dexcom Becomes Team Novo Nordisk's Official CGM Partner, Releases Report Citing Three Type 2 Care Challenges Across Eight Countries
New global State of Type 2 Report uncovers three interconnected challenges in Type 2 diabetes care: health literacy, technology literacy and systemic access.1New partnership reinforces Dexcom’s commitment to advancing